Here, we investigated the efficacy of nivolumab maintenance following platinum‐based chemotherapy in patients with EGFR‐mutant non‐small cell lung cancer (NSCLC) with disease progression after EGFR‐TKI. Here, EGFR is linked to non-small cell lung carcinoma.